The Conversation (0)
GeoVax Labs announced a significant update on the development of a vaccine candidate against Lassa hemorrhagic fever virus.
GeoVax Labs (OTCQB:GOVX) announced a significant update on the development of a vaccine candidate against Lassa hemorrhagic fever virus.
As quoted in the press release:
Efficacy testing in a murine challenge model (using a LASV reassortant) showed a single dose of the candidate vaccine, GEO-LM01, provided 100% protection to mice infected with a lethal dose of the challenge virus.
During testing, mice were given a single-dose vaccination of GEO-LM01 into muscle tissue, then infected with 1000 Plaque Forming Unit of the challenge virus by intracranial inoculation. All vaccinated mice survived whereas all unvaccinated mice died within one week of infection. Vaccinated animals produced a strong T cell immune response against LASV at 10 days post vaccination. The study was conducted at the Institute of Human Virology at the University of Maryland School of Medicine in Baltimore. A repeat of the study confirmed the findings.
“The fact that the GeoVax platform combines variable (glycoprotein) and conserved (matrix protein) antigens should broaden its protective capabilities and reduce the severity of infection by related pathogens”, noted Dr. Maria Salvato, Professor of Medicine, Institute of Human Virology, at the University of Maryland School of Medicine.
Click here to read the full press release.
Source: www.marketwired.com